<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: We tested the hypothesis that administration of the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> tirilazad mesylate improves electrophysiological recovery and decreases <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in cats </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: <z:chebi fb="2" ids="5615">Halothane</z:chebi>-anesthetized cats underwent 90 minutes of left middle cerebral artery and bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 180 minutes of reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Cats were assigned to receive tirilazad (1.5 mg/kg plus 0.2 mg/kg per hour IV infusion) either at the beginning (n = 9) or conclusion (n = 9) of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Control cats received an equal volume of diluent (<z:chebi fb="2" ids="50744">citrate</z:chebi> buffer, pH 3.0; n = 7) at the beginning and conclusion of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in a blinded fashion </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was measured by 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Blood flow to the left temporoparietal cortex decreased to less than 10 mL/min per 100 g with <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> but was minimally affected on the right side </plain></SENT>
<SENT sid="6" pm="."><plain>Blood flow distribution during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or reperfusion was not different in the tirilazad-treated groups </plain></SENT>
<SENT sid="7" pm="."><plain>No group demonstrated postischemic hyperemia or delayed hypoperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>Somatosensory evoked potential recorded over the left cortex was ablated during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and recovered to less than 15% of baseline amplitude at 180 minutes of reperfusion in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="9" pm="."><plain>There were no differences among groups in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume of left hemisphere (pretreatment, 25 +/- 6% [mean +/- SE]; posttreatment, 33 +/- 5%; control, 28 +/- 8% of hemisphere) or caudate nucleus (pretreatment, 46 +/- 7%; posttreatment, 41 +/- 10%; control, 55 +/- 13% of hemisphere) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In an experimental model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> involving severe reductions of blood flow followed by reperfusion in cats, administration of tirilazad at the <z:hpo ids='HP_0003674'>onset</z:hpo> of either <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or reperfusion does not ameliorate <z:mpath ids='MPATH_124'>infarct</z:mpath> volume assessed during early reperfusion </plain></SENT>
<SENT sid="11" pm="."><plain>Our study does not address potential efficacy of tirilazad in the setting of a different dosing strategy or duration of reperfusion </plain></SENT>
</text></document>